CN1556693A - 用于预防和治疗臭汗症的药剂 - Google Patents
用于预防和治疗臭汗症的药剂 Download PDFInfo
- Publication number
- CN1556693A CN1556693A CNA028185765A CN02818576A CN1556693A CN 1556693 A CN1556693 A CN 1556693A CN A028185765 A CNA028185765 A CN A028185765A CN 02818576 A CN02818576 A CN 02818576A CN 1556693 A CN1556693 A CN 1556693A
- Authority
- CN
- China
- Prior art keywords
- botulinum toxin
- body odor
- skin
- patient
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title 1
- 206010040904 Skin odour abnormal Diseases 0.000 claims abstract description 40
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 25
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 25
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 208000035985 Body Odor Diseases 0.000 claims description 33
- 210000004243 sweat Anatomy 0.000 claims description 13
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 4
- 101710182223 Toxin B Proteins 0.000 claims description 2
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 claims 1
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 claims 1
- 101000822778 Naja naja Long neurotoxin 4 Proteins 0.000 claims 1
- 101000822797 Naja naja Long neurotoxin 5 Proteins 0.000 claims 1
- 108010010958 snake venom neurotoxin F Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 18
- 230000035943 smell Effects 0.000 description 17
- 230000002159 abnormal effect Effects 0.000 description 15
- 241000358276 Cryptoprocta ferox Species 0.000 description 13
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 208000008454 Hyperhidrosis Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 235000019615 sensations Nutrition 0.000 description 9
- 230000037315 hyperhidrosis Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 7
- 230000001166 anti-perspirative effect Effects 0.000 description 6
- 239000003213 antiperspirant Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001104 scent gland Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241001062472 Stokellia anisodon Species 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 229940089093 botox Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000000106 sweat gland Anatomy 0.000 description 3
- 230000009967 tasteless effect Effects 0.000 description 3
- 241000193155 Clostridium botulinum Species 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001436672 Bhatia Species 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002665 ion therapy Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及肉毒杆菌毒素在制造用于预防及/或治疗臭汗症的药剂以及在制造用于改善体臭的化妆工具中的用途。
Description
技术领域
本发明涉及肉毒杆菌毒素(botulinus toxin)在制造用于预防及/或治疗臭汗症(bromhidrosis)的药剂以及在制造用于改善体臭的化妆工具(cosmetic means)中的用途。
背景技术
于化妆学中，有多种方法使用外来物质(香料)来产生令人愉悦的气味；于医学中，也有方法用来减低病理性的、难闻的体臭(臭汗症(bromhydrosis))。不过，两者都不外乎用来增加体味的品质等级或可接受性之可能性。
体臭系一种一般已知且广布的现象。其可能在类似的状况下以非常不同的强度发生于不同的个体且会给罹患的人本身及其同伴不同的感觉。
与通常的观念不同的是，体汗，亦即外分泌汗腺的分泌物，是完全无味的。所以过度的出汗不能与过度的体味混淆。于其组成中，汗液为一种透明的水性液体，主要包括钠、钾、钙、镁和氯等离子且除此之外还含有乳酸盐、尿素与微量氨基酸、生物胺类(biogenic amines)及维生素。在特殊情况中也可能透过出汗而排出药剂例如灰黄霉素(griseofulvin)与酮康唑(ketokonazol)，不过这些对于体臭并没有明显的作用。产生的汗液愈多，例如在极端情况像在蒸气浴室中，汗会更为稀释，亦即，所有的汗会变得更为水性。在正常生理状况下过度非自然性的汗产生即称为一种病态，所谓的多汗症(hyperhidrosis)。所以过度的出汗(多汗)不是体味的直接原因。相反地，在医学教科书和刊物中明确地强调患有过度腋下出汗(腋多汗(Hyperhidrosis axillaris))的病人通常不会发展出强烈体臭[4]。此点可以由巨量流出的汗好似从皮肤“冲洗掉”味道产生性物质之事实予以解释。不过，与分泌汗腺不同，所谓的气味腺(the scent ligand)(顶泌腺(apocrine ligand)与顶-外分泌腺(apo-eccrinegland)可能释放出可辨出的嗅觉性分泌物。此种分泌物可能转而在皮肤表面上被细菌转化成恶臭物质。所以可以指称气味腺于体臭发生中具有肇始作用。气味腺可能数目巨大，例如在人体的腋窝内，不过其通常是在青春期以后才具有活性。因此，在成人期通常具有比儿童期远较为强烈的体臭。
简言之，体臭可能由两项必要因素所产生：
1.由气味腺产生的分泌物显示出会被其它人以非常不同的程度所觉察出之特性味道。
2.气味腺的分泌物、类固醇衍生物与其它身体物质例如皮肤的油脂，可能被皮肤上的微生物区系(microflora)所降解，产生一系列的分解产物。此等由细菌产生的分解产物可能产生例如刺鼻性或腐臭气味。某些氨基酸也可能造成体臭。
因此总的说来体臭大部份为多种不同成分的混合物质，其组成尚未被完全分析过且不同个体之间可能非常地不同。因此，有关体臭的分析，不是仅仅通过生物化学测量而进行，而是由进行体臭评定的独立的人员采用他们的嗅觉器官进行，且以此方式在平分表上指出某一气味的强烈程度或使人不愉快的程度。
对于极端强烈且使人不愉快的情况，体臭被定义为一种称为“臭汗症”的疾病。不过，体臭也可能在从使人不愉快、讨厌到讨人喜欢或甚至于使人着迷或兴奋的广泛范围内为人所察觉。因此，于行为心理学中，体臭的影响不仅由强度(某物质嗅起来多强烈)而且也由情绪价(emotional valence)(某物质嗅起来多好或多坏)予以判断。
于今所知要获得讨人喜欢的体味之方法基本上包括使用来覆盖本身体味的香水、香料、物质与除臭剂。
此外，减低讨厌的体臭所用的治疗法主要针对皮肤细菌及其在皮肤上的分解活性。因此，于有臭汗症的情况中，建议例如下列事项：
●经常洗涤及更换内衣
●经常使用肥皂或合成洗涤剂(syndets)以洗清有强烈味道的物质
●使用除臭剂
●使用消毒剂或皮肤清洁剂以分别地减低或破坏皮肤菌群。
上面所提及的作法之缺点在于：愈广泛地使用这些措施，愈导致其对皮肤的刺激以及对皮肤作为屏障的功能之干扰，其可能导致讨厌的似湿疹反应而伴随着发红与搔痒。此外，在除臭剂内的香料物质特别会展现出高变态反应性(allergenic power)而促成一种免疫性变态反应性作用(immunological allergisation)导致毕生存在的变态反应。
虽然有建议采用对汗分泌的压制，例如经由使用含金属盐如氯化铝的溶液，来促成对汗腺通道的机械性堵塞，由此抑制流汗。不过，这些与类似的治疗法也时常会导致对皮肤产生讨厌的刺激作用。再者，考虑到上面所提及的汗的无味特点，这些方法也不适合于用来直接影响体臭，反而最好是对皮肤环境产生间接的改变。
因此，总而言之，所有常规作法都忽视气味腺以及对其进行操作以改善体臭的重要性。
所以，本发明的问题包括提供用于治疗臭汗症所用的药剂以及提供用于改善体臭的化妆工具。
这些问题由本申请的权利要求书中所界定的主题予以解决。
发明内容
本发明的一方面涉及肉毒杆菌毒素在制造用于预防或治疗臭汗症的药剂中的用途。本发明的另一方面涉及肉毒杆菌毒素在制造用于改善体臭的化妆剂中的用途。
因此，本发明涉及一种新的处理体臭之方法，例如使体臭减轻(较不强烈)和改善(感觉更令人喜悦)的方法。由于汗液是一种无味的流体，因此该方法不仅仅是要减少汗液的分泌，而是要改变产生可察觉的且令人讨厌的臭味的腋窝或其它皮肤部位的气味的特征。
附图说明
本发明要用下面的图式予以示范说明。
图1显示出使用肉毒杆菌毒素于一侧处理后的体臭强度评估(0＝没有可察觉的气味，6＝最强烈的气味)。对照处理腋窝：n＝16，中位数＝2.88，SD＝1.43。肉毒杆菌毒素-A-处理腋窝：n＝16，中位数＝1.75，SD＝0.86。显著性差异(Wilcoxon-test)：p＝0.02。BTA指肉毒杆菌毒素-A。
图2显示出使用肉毒杆菌毒素一侧处理后的体臭品质等级(价)评估(-3＝极端讨厌；+3＝极端令人喜悦)。对照处理腋窝：n＝16，中位数＝-1.13，SD＝0.89。肉毒杆菌毒素-A处理腋窝：n＝16，中位数＝0.5，SD＝0.75。显著性差异(Wilcoxon-test)：p＝0.001。BTA指肉毒杆菌毒素-A。
具体实施方式
肉毒杆菌毒素是由肉毒杆菌(Clostridium botulinum)在厌氧(anaerobic)条件下产生的一组高效力细菌毒素。自1989年之后在美国且自1991与1993年之后在德国，亚型肉毒杆菌毒素-A即分别经认可作为一种药用剂用以治疗选定的神经肌肉疾病。于德国，肉毒杆菌毒素-A的商品名有Botox(Merz，Frankfurt公司所经销；制造：Allergan，IrvineCa.，USA)与Dysport(Ispen-pharma，Ettlingen公司所经销)之下取得。自2001年之后，出现了名称为NeuroBloc(company Elan，Munich)的含有亚型肉毒杆菌毒素-B的另一种制剂。
肉毒杆菌毒素的药理学、药剂制造以及许多临床应用都在技术文献中有详细地说明[1，2]。肉毒杆菌毒素的临床效应在于其对乙酰胆碱(acetylcholine)释放的阻断。如此一来，使用乙酰胆碱作为递质(transmitter)的所有神经末端都可能被阻断。
肉毒杆菌毒素-A在过度发汗(多汗症)治疗中的成功应用已经在技术文献中有重复地述及[3]。但是，对于体臭的影响则至今尚未听闻。事实上，倒是在一篇有关多汗症的治疗之科学文章中讨论到肉毒杆菌毒素的注射对于体臭没有影响[3]。
不过，本发明人在临床观察中惊讶地发现肉毒杆菌毒素对于臭汗症的情况有效用且甚至可改善健康人的体臭。后者绝对不是成功的臭汗症治疗之必然结果，因为讨厌的、甚至是病理性的体臭的减轻应该只是会导致较低困扰性或最多不过是中性的体味，而不会导致产生一种不同的、正面的体味。
所以，本发明的一方面在于提供一种物质，其导致身体本身的气味对其同伴分别显示出逐渐增强的正面及更愉悦的影响且因而在所有嗅觉起着一种直接或间接的影响的人际关系的情况中给使用者产生竞争优势。
于此种情况中肉毒杆菌毒素不仅可以用其野生型形式而且可以用其衍生物、片段或有经过各种各样改变例如化学修饰的肉毒杆菌毒素。于此“衍生物”意指肉毒杆菌毒素的氨基酸序列可能包含取代、缺失、插入或添加。于此，“片段”意指只有某些部份的肉毒杆菌毒素可以使用，只要该部份显示出野生型肉毒杆菌毒素所具生物活性即可。
优选地，肉毒杆菌毒素系经由皮内注射而导入皮肤之内。这可以经由使用例如分别附有紧急皮下针头与常规针头(例如30号针)的注射器或以任何别的注射方法(例如分别为高压注射与无针头注射)予以完成。注射要在欲处理的皮肤部位上面均匀地分布例如以0.5至5厘米的距离分布。也可以使用其它种注射法例如皮下或表皮内注射。
其它的施用形式例如敷用一种适当的、有或没有辅助皮肤渗透的添加剂的制剂(例如凝胶、乳膏、软膏、喷剂)中的肉毒杆菌毒素，也适合所用，只要能提供活性剂的透皮吸收即可。同样地，可以使用水浴或含溶剂的浴于有或没有施加微弱的电流之下(离子电渗法(iontophoresis))将活性剂分别施加到皮肤上并导入皮肤内。
优选地制备成即用型肉毒杆菌毒素注射溶液。此类溶液可以经由例如将一包装单位的制剂Botox或制剂Dysport溶解在无菌生理盐水溶液(例如自由决定的1-10毫升体积)之内而制备成。或者使用已经可以取得为溶解形式的制剂Neurobloc。或者分别使用任何亚型的肉毒杆菌毒素(例如A、B、C、D、E、F、G)及这些肉毒杆菌毒素的衍生物、片段或有任何方面的改变之形式。或者分别使用适合于上面所提施药方式的数种肉毒杆菌毒素亚型的组合或与其它物质和辅助性物质的组合。活性剂在溶液中的浓度(以小鼠单位/毫升测定)可以根据个别需要与经验而自由地选用。
优选地，腋窝为适合治疗的部位，不过，任何其它身体区位都可以用其来治疗，例如鼠蹊区、臀部、足部。任何形式的支持性预-处理或后-处理，例如敷用止痛膏、冷却、皮肤浸渍或会改变气味的乳膏或软膏、或任何类型的外部施药，都可以与上面所提诸种施药形式之一组合地使用。
下面的实施例用来阐明本发明而不可误解为要用来限制本发明。
实施例
实施例1-医案研究(casuistics)
一个患有从腋窝散发出的强烈体臭之患者接受使用溶解在2毫升NaCl内的50单位Botox分布在每腋窝10个皮内注射点之治疗。于一星期之后，虽然还是具有相同的卫生习惯，不过检查到其体臭强度有显著地减低。
实施例2-初步研究
对一组16个试验人员于教育与以书写形式同意之后进行检测。对每一试验人员都要求不要使用除臭剂、香水或香皂等，不要食用洋葱、龙须菜或大蒜且与伴侣不亲密或亲近接触三天。于第三天要求每一试验人员穿上一件白色的T恤(100％棉，预先洗过)从中午到中午共24小时。于此之后，将T恤腋下部份切下并分开地放置到可气密地封锁住之玻璃烧瓶之内。将这些样品匿名地标记后，呈现给参与者作为嗅觉样品，每一参与者都嗅所有的嗅觉样品，但都不知道样品是从何人所得。于此之后，每一参与者都接受在两腋窝中每侧10切入点之注射治疗。于其中一侧系施用溶解在2毫升等张NaCl溶液内的100单位肉毒杆菌毒素-A(Dysport)而于另一侧系施用2毫升的等张生理盐水溶液。医师或参与者都不知道那一侧是用活性剂处理或用对照溶液处理(双盲式)。于一星期之后，在完全相同的条件之下重复T-恤嗅觉试验。在统计分析之后，发现在两边之间具有高度显著性差异：用肉毒杆菌毒素处理的腋窝与T恤切片分别嗅起来都比对照分别较不强烈且较不令人讨厌与更令人愉悦。
实施例3-初步研究
要求56个女人评估前面16个供应者的嗅觉样品。嗅觉样品的准备所用方法类似于实施例2，亦即从每一供应者得到2个样品：一者系来自经肉毒杆菌毒素-处理的腋窝；另一者系得自未经处理的腋窝。
所有女人都被要求评估下列诸项：
1.两个样品中哪一个嗅起来较为令人愉悦(双盲方式)？
2.嗅觉品质如何：(7分范围，从-3＝非常令人讨厌，经过0＝中性，到+3＝非常愉悦)？
3.你如何描述该气味(给出正面或负面形容词以供选择，例如花香相对于脓臭，水果香相对于腐臭味等)？
4.在觉察此气味时你的感觉如何(9分价)？
5.你能想要拥有此种气味的伴侣吗？
6.有关此气味你心理会出现什幺？
分析：对重复的象征性数据点(nominal data point)所得测量值利用McNemar x2-试验计算配对式比较。
用肉毒杆菌毒素处理过的一侧之气味都高度显著地感觉为更令人愉悦(p＜0.001)且在直接比较与根据评分范围两者中都是如此。对于肉毒杆菌毒素处理过的样品更明显地使用到正面的形容词。于感受经肉毒杆菌毒素处理过的样品之情况中，女人都感觉高度明显地“更牢靠”(securer)与“更快乐”(happier)且相对于具有未处理样品所具气味者，她们也可能更明显地想象要拥有具有经肉毒杆菌毒素处理过的样品所具气味之伴侣。
参考文献
1.Huang W，Foster JA，Rogachefsky AS(2000)：Pharmacology ofbotulinum toxin.J Am Acad Dermatol 43：249-59
2.Munchau A，Bhatia KP(2000)：Uses of botulinum toxin injection inmedicine today.BMJ 320：161-5
3.Naumann M，Hofmann U，Bergmann I，Hamm H，Toyka KV，ReinersK(1998)：Focal hyperhidrosis：effective treatment with intracutaneousbotulinum toxin[see comments].Arch Dermatol 134：301-4
4.Sato K，Kang WH，Saga K，Sato KT(1989)：Biology of sweat glandsand their disorders.II.Disorders of sweat gland function.J Am AcadDermatol 20：713-726
Claims (3)
1、肉毒杆菌毒素在制造用于预防及/或治疗臭汗症以及用于改善普通的体臭的药剂中的用途。
2、肉毒杆菌毒素在制造用于改善普通的体臭的化妆工具中的用途。
3、权利要求1或2的用途，其中所述的肉毒杆菌毒素选自肉毒杆菌毒素A、B、C、D、E、F或G型或其衍生物或片段。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10146647.1 | 2001-09-21 | ||
| DE10146647A DE10146647A1 (de) | 2001-09-21 | 2001-09-21 | Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1556693A true CN1556693A (zh) | 2004-12-22 |
| CN1289061C CN1289061C (zh) | 2006-12-13 |
Family
ID=7699852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028185765A Expired - Fee Related CN1289061C (zh) | 2001-09-21 | 2002-09-23 | 用于预防和治疗臭汗症的药剂 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050036966A1 (zh) |
| EP (2) | EP2987483B1 (zh) |
| JP (1) | JP4966478B2 (zh) |
| KR (1) | KR100796243B1 (zh) |
| CN (1) | CN1289061C (zh) |
| AU (1) | AU2002349268B2 (zh) |
| CA (1) | CA2461117C (zh) |
| DE (1) | DE10146647A1 (zh) |
| EA (2) | EA008146B1 (zh) |
| HU (1) | HU230398B1 (zh) |
| IL (2) | IL160875A0 (zh) |
| MX (1) | MXPA04002614A (zh) |
| PL (1) | PL209639B1 (zh) |
| UA (1) | UA78718C2 (zh) |
| WO (1) | WO2003026602A2 (zh) |
| ZA (1) | ZA200402123B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101171018B (zh) * | 2005-03-03 | 2013-03-27 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113349A1 (en) | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
| US7288259B2 (en) | 2002-08-19 | 2007-10-30 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7335367B2 (en) * | 2003-03-06 | 2008-02-26 | Botulinum Toxin Research Associates, Inc. | Treatment of chronic chalazion and hordeolum with botulinum toxin |
| US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| WO2008070538A2 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
| KR101848095B1 (ko) * | 2008-06-26 | 2018-04-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| US8454975B1 (en) * | 2010-01-11 | 2013-06-04 | Elizabeth VanderVeer | Method for enhancing skin appearance |
| MX2019005833A (es) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| EP3843777A4 (en) | 2018-08-28 | 2022-05-04 | Ira Sanders | THERAPEUTICS FOR THE SKIN |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19852981A1 (de) * | 1998-11-17 | 2000-05-18 | Martin Schmidt | Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen |
| US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
-
2001
- 2001-09-21 DE DE10146647A patent/DE10146647A1/de not_active Ceased
-
2002
- 2002-09-23 UA UA20040402705A patent/UA78718C2/uk unknown
- 2002-09-23 JP JP2003530240A patent/JP4966478B2/ja not_active Expired - Lifetime
- 2002-09-23 KR KR1020047004120A patent/KR100796243B1/ko active IP Right Grant
- 2002-09-23 AU AU2002349268A patent/AU2002349268B2/en not_active Ceased
- 2002-09-23 EP EP15179974.9A patent/EP2987483B1/de not_active Expired - Lifetime
- 2002-09-23 US US10/490,244 patent/US20050036966A1/en not_active Abandoned
- 2002-09-23 HU HU0401913A patent/HU230398B1/hu not_active IP Right Cessation
- 2002-09-23 IL IL16087502A patent/IL160875A0/xx unknown
- 2002-09-23 EA EA200400436A patent/EA008146B1/ru unknown
- 2002-09-23 MX MXPA04002614A patent/MXPA04002614A/es active IP Right Grant
- 2002-09-23 EA EA200601238A patent/EA011988B1/ru unknown
- 2002-09-23 EP EP02781099.3A patent/EP1427385B1/de not_active Expired - Lifetime
- 2002-09-23 CA CA002461117A patent/CA2461117C/en not_active Expired - Lifetime
- 2002-09-23 PL PL373528A patent/PL209639B1/pl unknown
- 2002-09-23 CN CNB028185765A patent/CN1289061C/zh not_active Expired - Fee Related
- 2002-09-23 WO PCT/DE2002/003561 patent/WO2003026602A2/de active Application Filing
-
2004
- 2004-03-15 IL IL160875A patent/IL160875A/en active IP Right Grant
- 2004-03-17 ZA ZA200302123A patent/ZA200402123B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101171018B (zh) * | 2005-03-03 | 2013-03-27 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA200400436A1 (ru) | 2007-02-27 |
| EP1427385A2 (de) | 2004-06-16 |
| KR100796243B1 (ko) | 2008-01-21 |
| WO2003026602A3 (de) | 2003-08-28 |
| US20050036966A1 (en) | 2005-02-17 |
| MXPA04002614A (es) | 2005-02-17 |
| HU230398B1 (hu) | 2016-04-28 |
| EP2987483B1 (de) | 2020-12-02 |
| UA78718C2 (en) | 2007-04-25 |
| IL160875A0 (en) | 2004-08-31 |
| CA2461117A1 (en) | 2003-04-03 |
| IL160875A (en) | 2010-11-30 |
| CN1289061C (zh) | 2006-12-13 |
| EP2987483A1 (de) | 2016-02-24 |
| KR20040048895A (ko) | 2004-06-10 |
| JP2005507888A (ja) | 2005-03-24 |
| DE10146647A1 (de) | 2003-04-24 |
| EP1427385B1 (de) | 2015-09-23 |
| CA2461117C (en) | 2009-12-08 |
| WO2003026602A2 (de) | 2003-04-03 |
| HUP0401913A2 (hu) | 2005-01-28 |
| PL209639B1 (pl) | 2011-09-30 |
| EA200601238A1 (ru) | 2007-06-29 |
| JP4966478B2 (ja) | 2012-07-04 |
| AU2002349268B2 (en) | 2007-12-13 |
| ZA200402123B (en) | 2004-10-04 |
| PL373528A1 (en) | 2005-09-05 |
| EA011988B1 (ru) | 2009-06-30 |
| HUP0401913A3 (en) | 2008-02-28 |
| EA008146B1 (ru) | 2007-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1289061C (zh) | 用于预防和治疗臭汗症的药剂 | |
| Mazzoni et al. | Role of dentin MMPs in caries progression and bond stability | |
| Ricketts | Management of the deep carious lesion and the vital pulp dentine complex | |
| Dammaschke et al. | Histocytological evaluation of the reaction of rat pulp tissue to Carisolv | |
| Sharma et al. | Evidence of variable bacterial colonization on coloured elastomeric ligatures during orthodontic treatment: An intermodular comparative study | |
| Ma et al. | Effect of lemon essential oil on halitosis | |
| Garcia-Contreras et al. | A comparative in vitro efficacy of conventional rotatory and chemomechanical caries removal: Influence on cariogenic flora, microhardness, and residual composition | |
| CN111093611B (zh) | 用于在降低或预防体味时应用的短杆菌素及其制剂 | |
| Thioly-Bensoussan | Non–hyaluronic acid fillers | |
| Ahn et al. | A clinical study of micronized acellular dermal matrix collagen paste application with negative pressure wound therapy | |
| Pessemier et al. | Underarm body odor, the microbiome, and probiotic treatment | |
| Bai et al. | Tonsillolith: A polymicrobial biofilm | |
| Heckmann et al. | Making scents: Improvement of olfactory profile after botulinum toxin‐A treatment in healthy individuals | |
| Bhambri | Role of Oral Microbial Flora in Health and Illness | |
| Maashi | Clinical and Microbiological Evaluation of Two Chemomechanical Caries Removal Agents in Primary Molars: A Randomized Controlled Study | |
| Ravindra et al. | Olfactory diagnosis in skin | |
| Issa et al. | Barbizan de Moura, LH Global Facial Rejuvenation Using a New Cohesive, Highly Concentrated Hyaluronic Acid Filler: A Descriptive Analysis of 35 Cases. Cosmetics 2023, 10, 105 | |
| Mohamed Ahmed | Novel approach to treat root caries: A pilot study to investigate Chlorhexidine-modified Glass Ionomer Cement applied using ART | |
| El-desoki et al. | Effect of glycolic acid as single irrigant versus sodium hypochlorite and EDTA on enterococcus faecalis count and smear layer removal in single-rooted teeth (an in vitro study) | |
| Widjojo | In Vitro Methods of Antimicrobial Activity Measurement of Erha’s Deodorant on Staphylococcus Hominis and Micrococcus Luteus | |
| JP2007045796A (ja) | 口腔用固形製剤 | |
| WO2024118975A1 (en) | Ingredient mixtures effective to modify ratios of beneficial microbial species to non-beneficial microbial species mixtures | |
| KAVALAKKATT et al. | MELIOIDOSIS SEPTICEMIA WITH MUSCULOSKELETAL INVOLVEMENT: A CASE REPORT. | |
| Dinesh Karthick et al. | Comparative evaluation of oil pulling and chlorhexidine mouthwash in halitosis: A randomized controlled trial | |
| CN1875942A (zh) | 抑汗、除臭外用喷雾剂配方 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ALEGAN CO.,LTD. Free format text: FORMER OWNER: MAKEHAIKEMAN Effective date: 20060127 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060127 Address after: American California Applicant after: ALLERGAN, Inc. Address before: German Bochim Applicant before: Heckmann Marc |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20210923 |